Recently presented at the American Society ofClinical Oncology (ASCO) Annual Meeting, a phase II trial of erlotinib inpreviously untreated NSCLC patients with mutations of the tyrosine kinasedomain of EGFR was evaluated. Here, EGFR is linked to non-small cell lung carcinoma.